Justin Klee (L) and Josh Cohen (Amylyx)
Amylyx snatched the landmark approval for its ALS drug. Now it’s seeking cash to foot the launch bill
As Amylyx gets ready to debut its ALS drug in the US — amid scrutiny and criticism of the price it’s set — the biotech is going …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
